TY - JOUR
T1 - Oromucosal films
T2 - from patient centricity to production by printing techniques
AU - Tian, Yu
AU - Orlu, Mine
AU - Woerdenbag, Herman J.
AU - Scarpa, Mariagiovanna
AU - Kiefer, Olga
AU - Kottke, Dina
AU - Sjoholm, Erica
AU - Oblom, Heidi
AU - Sandler, Niklas
AU - Hinrichs, Wouter L. J.
AU - Frijlink, Henderik W.
AU - Breitkreutz, Jorg
AU - Visser, J. Carolina
PY - 2019
Y1 - 2019
N2 - Introduction: Oromucosal films, comprising mucoadhesive buccal films (MBFs) and orodispersible films (ODFs), are considered patient-centric dosage forms. Target groups are patients with special needs. Various active pharmaceutical ingredients have been shown to be suitable for oromucosal film production. A shift is seen in the production techniques, from conventional solvent casting to printing techniques. Areas covered: In this review, the patient acceptability of oromucosal films is discussed. An overview is given of the small molecule drugs, biopharmaceuticals and herbal extracts that have been incorporated so far. Finally, the current state of 2D and 3D printing techniques for production purposes is discussed. Expert opinion: The patient-centric features are important for the further development and acceptance of this oral solid dosage form. Oromucosal films perfectly fit in the current attention for personalized medicine. Both MBFs and ODFs are intended for either a local or a systemic effect. For buccal absorption, sufficient mucoadhesion is one of the most important criteria an oromucosal film must comply with. For the preparation, the solvent casting technique is still predominately used. Some limitations of this production method can be tackled by printing techniques. However, these novel techniques introduce new requirements, yet to be set, for oromucosal film preparation.
AB - Introduction: Oromucosal films, comprising mucoadhesive buccal films (MBFs) and orodispersible films (ODFs), are considered patient-centric dosage forms. Target groups are patients with special needs. Various active pharmaceutical ingredients have been shown to be suitable for oromucosal film production. A shift is seen in the production techniques, from conventional solvent casting to printing techniques. Areas covered: In this review, the patient acceptability of oromucosal films is discussed. An overview is given of the small molecule drugs, biopharmaceuticals and herbal extracts that have been incorporated so far. Finally, the current state of 2D and 3D printing techniques for production purposes is discussed. Expert opinion: The patient-centric features are important for the further development and acceptance of this oral solid dosage form. Oromucosal films perfectly fit in the current attention for personalized medicine. Both MBFs and ODFs are intended for either a local or a systemic effect. For buccal absorption, sufficient mucoadhesion is one of the most important criteria an oromucosal film must comply with. For the preparation, the solvent casting technique is still predominately used. Some limitations of this production method can be tackled by printing techniques. However, these novel techniques introduce new requirements, yet to be set, for oromucosal film preparation.
KW - Local drug delivery
KW - mucoadhesive buccal films
KW - orodispersible films
KW - oromucosal films
KW - patient centricity
KW - printing techniques
KW - systemic drug delivery
KW - MUCOADHESIVE BUCCAL FILMS
KW - CRITICAL MATERIAL ATTRIBUTES
KW - IN-VITRO EVALUATION
KW - ORAL DOSAGE FORMS
KW - ORODISPERSIBLE FILMS
KW - DRUG NANOPARTICLES
KW - VIVO EVALUATION
KW - BUCCOADHESIVE FILM
KW - DELIVERY-SYSTEM
KW - FORMULATION
U2 - 10.1080/17425247.2019.1652595
DO - 10.1080/17425247.2019.1652595
M3 - Review article
SN - 1742-5247
VL - 16
SP - 981
EP - 993
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
IS - 9
ER -